Real-World Outcomes Of Standalone Istent Inject W Implantation: 12-Month Results

The efficacy of iStent inject implantation in conjunction with phacoemulsification has been well-established. The purpose of this study was to investigate the IOP-lowering efficacy and safety of standalone iStent inject W implantation over 12 months.

Single surgeon (Dr GV) at Hospital of Legnago, Verona, Italy

Retrospective, non-randomized case series review of surgeries where iStent inject W (n = 53 patients) were implanted without concurrent phacoemulsification. Main outcome measures were intraocular pressure (IOP), number of medications, and post-op complications. Outcomes were compared using paired Student’s t-test.

Mean pre-operative IOP was 20.4 ± 1.8 mmHg on an average of 2.5 ± 0.8 medications. One week post-operative, IOP had decreased to 15.2 ± 2.6 mmHg and remained low throughout the course of the study. After 12 months, patients’ mean IOP was 16.3. ± 2.3 mmHg on an average of 1.3 ± 1.3 medications. After 12 months post-op, 55.8% of patients had IOP reductions > 20% from baseline. Furthermore, 12 months post-op, 28% of patients remained medication-free, compared to no patients prior to surgery. The safety of the procedure was excellent, with more than 90% of patients developing no post-op complications.

iStent inject W reduced IOP and medication burden for up to 12 months in patients with open-angle glaucoma. It can also be considered a safe surgery, with a very low rate of complications.